Trifluoroacetic Acid

Trifluoroacetic Acid

SCHEMBL7346166

N=C(N)c1ccc2cc(/C=C/c3ccc(C(N)=O)cc3)ccc2c1.O=C(O)C(F)(F)F

nearest known ligand 0.66

Full drug profile on Sugi Atlas →

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
PLAU P00749 14/20 0.66
PLG P00747 6/20 0.66
KLK1 P06870 5/20 0.66
PLAT P00750 3/20 0.66
F2 P00734 3/20 0.49
KLKB1 P03952 3/20 0.49
PRSS1 P07477 3/20 0.49
PRMT1 Q99873 3/20 0.46
PRMT5 O14744 1/20 0.46
ALDH1A1 P00352 1/20 0.46
HPGD P15428 1/20 0.46
CYP2C19 P33261 1/20 0.46
HSD17B10 Q99714 1/20 0.46
F12 P00748 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL7338603 0.92 PLAU (0.66) PLAUPLGKLK1PLATF2
Trifluoroacetic Acid SCHEMBL7336137 0.92 PLAU (0.79) PLAUPLGKLK1PLATF2
SCHEMBL27536270 0.90 PLAU (0.74) PLAUPLGKLK1PLATF2
Trifluoroacetic Acid SCHEMBL7335295 0.87 PLAU (0.59) PLAUPLGKLK1PLATF2
Trifluoroacetic Acid SCHEMBL7341731 0.85 PLAU (0.56) PLAUPLGKLK1PLATF2
Trifluoroacetic Acid SCHEMBL7341738 0.85 PLAU (0.56) PLAUPLGKLK1PLATF2
Trifluoroacetic Acid SCHEMBL7346156 0.83 PLAU (0.44) PLAUPLGKLK1PLATALDH1A1
Trifluoroacetic Acid SCHEMBL7346179 0.83 PLAU (0.44) PLAUPLGKLK1PLATALDH1A1
Trifluoroacetic Acid SCHEMBL7337163 0.82 PLAU (0.56) PLAUPLGKLK1PLATF2
Trifluoroacetic Acid SCHEMBL7853387 0.82 PLAU (0.66) PLAUPLGKLK1PLATF2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20010049374-A1 Urokinase inhibitors STEELE ANDREW W (US) 2001-12-06 US disclosed
US-6284796-B1 NAPHTHAMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-09-04 US disclosed
US-6258822-B1 ENZYME INHIBITORS OF NAPHTHALENE AMIDINE COMPOUNDS ABBOTT LABORATORIES 2001-07-10 US disclosed
EP-1000018-A2 UROKINASE INHIBITORS Abbott Laboratories (US) 2000-05-17 EP disclosed
WO-1999005096-A2 UROKINASE INHIBITORS ABBOTT LABORATORIES (US) 1999-02-04 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010049374-A1 Urokinase inhibitors SERPINE1, PLAU, SERPINB1 PLAU 2/4885PLG 10/4885KLK1 62/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.